Related Experiment Videos
One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling
1Department of Paediatric Nephrology and Metabolic Disorders, Childrens Hospital Medical School, Hannover, Federal Republic of Germany.
Pediatric Nephrology (Berlin, Germany)
|September 1, 1990
Abstract:
Fourteen patients (aged 5.9-22.1 years) undergoing continuous ambulatory or cycling peritoneal dialysis were treated with recombinant human erythropoietin (rhEPO), which was given intravenously once a week at a dosage of 300 units/kg. The mean haematocrit level increased from 18.5% to 27.5% and the reticulocyte count from 19% to 62% within 1 month. After an average time of 3.1 months rhEPO dosage could be adjusted to 100 units/kg per week to keep the haematocrit level at 30%. Only 1 patient had an exacerbation of hypertension, which required a dosage reduction; other side-effects were not noted.